All Articles: Public Health
YCT-529 continues to progress efficiently in clinical studies.
Dr. Carolyn Fairbanks, associate dean for research and professor in pharmaceutics, leads a research team that has designed, synthesized, and characterized new molecules that could reduce chronic pain without the side effects often associated with opioids.
PharmD alumna Dr. Holly Drone is tackling the opioid crisis systemically. As a clinical pharmacist in emergency medicine and in Hennepin Emergency Medical Services, she co-leads a team of six paramedics specially trained in caring for patients who have overdosed or live with opioid use disorder.
Results from the first in-human clinical trial of YCT-529, a hormone-free birth control pill for men developed by Dr. Gunda Georg and her team at the College of Pharmacy and YourChoice Therapeutics, showed that the contraceptive was well tolerated.
Could researchers examine someone's online activity as a form of clinical observation? Dr. Jude Mikal is seeking funding for research that would help intervene earlier on in the progression of dementia.
A $3.8 million National Institutes of Health (NIH) grant will fund research led by the University of Minnesota Center for Drug Design (CDD) in collaboration with Texas A&M University aiming to create antiviral drugs for the treatment of Mpox.
Duerfeldt's research is focused on the development of chemical tools that can be utilized to enhance our understanding of disease mechanisms and the development of new therapeutic leads for bacterial infections and ocular diseases.
The term of service runs January 2024 through January 2028.
The Medicinal Chemistry Department celebrates and honors Dr. Phillip S. Portoghese as he retires from the University after 62 years of exemplary teaching, research, and service.
A new publication in Nature Communications describes the development and mechanism of action of new allosteric inhibitors that show promise for further development into a selective but efficacious therapeutic.